Therapeutic potential of triple-negative breast cancer immune checkpoint blockers: A 21-year bibliometric analysis
This study revealed that ICB therapy for TNBC is a rapidly evolving and high-profile topic. Future research should focus on the optimal selection of different targets for ICB in combination with neoadjuvant chemotherapy, ADC, and poly ADP-ribose polymerase inhibitors to treat TNBC.
Authors
- Chundi Gao (ORCID: https://orcid.org/0000-0002-0795-0370)
- Zhongli Sun (ORCID: https://orcid.org/0000-0002-6528-9058)
- Longyun Wang
- Cun Liu (ORCID: https://orcid.org/0000-0001-8197-9000)
- Changgang Sun (ORCID: https://orcid.org/0000-0003-0778-8788)
- Ye Li (ORCID: https://orcid.org/0000-0001-7727-0875)
- Yan Yao (ORCID: https://orcid.org/0000-0003-3981-9112)
- Huayao Li (ORCID: https://orcid.org/0000-0003-2331-366X)
Institutions
- Macau University of Science and Technology (MO)
- Weifang Medical University (CN)
- Shandong University of Traditional Chinese Medicine (CN)
- Weifang Chinese Medicine Hospital (CN)
Publication Details
- Journal
- Medicine
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1097/md.0000000000041739
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05